Kathleen F Kerr1, Jeremy Roth1, Kehao Zhu1, Heather Thiessen-Philbrook2, Allison Meisner1, Francis Perry Wilson2, Steven Coca3, Chirag R Parikh2,4. 1. 1 Department of Biostatistics, University of Washington, Seattle, WA, USA. 2. 2 Program of Applied Translational Research, Yale University School of Medicine and VA Medical Center, New Haven, CT, USA. 3. 3 Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. 4 Section of Nephrology, Yale University School of Medicine, New Haven, CT, USA.
Abstract
BACKGROUND/AIMS: A potential use of biomarkers is to assist in prognostic enrichment of clinical trials, where only patients at relatively higher risk for an outcome of interest are eligible for the trial. We investigated methods for evaluating biomarkers for prognostic enrichment. METHODS: We identified five key considerations when considering a biomarker and a screening threshold for prognostic enrichment: (1) clinical trial sample size, (2) calendar time to enroll the trial, (3) total patient screening costs and the total per-patient trial costs, (4) generalizability of trial results, and (5) ethical evaluation of trial eligibility criteria. Items (1)-(3) are amenable to quantitative analysis. We developed the Biomarker Prognostic Enrichment Tool for evaluating biomarkers for prognostic enrichment at varying levels of screening stringency. RESULTS: We demonstrate that both modestly prognostic and strongly prognostic biomarkers can improve trial metrics using Biomarker Prognostic Enrichment Tool. Biomarker Prognostic Enrichment Tool is available as a webtool at http://prognosticenrichment.com and as a package for the R statistical computing platform. CONCLUSION: In some clinical settings, even biomarkers with modest prognostic performance can be useful for prognostic enrichment. In addition to the quantitative analysis provided by Biomarker Prognostic Enrichment Tool, investigators must consider the generalizability of trial results and evaluate the ethics of trial eligibility criteria.
BACKGROUND/AIMS: A potential use of biomarkers is to assist in prognostic enrichment of clinical trials, where only patients at relatively higher risk for an outcome of interest are eligible for the trial. We investigated methods for evaluating biomarkers for prognostic enrichment. METHODS: We identified five key considerations when considering a biomarker and a screening threshold for prognostic enrichment: (1) clinical trial sample size, (2) calendar time to enroll the trial, (3) total patient screening costs and the total per-patient trial costs, (4) generalizability of trial results, and (5) ethical evaluation of trial eligibility criteria. Items (1)-(3) are amenable to quantitative analysis. We developed the Biomarker Prognostic Enrichment Tool for evaluating biomarkers for prognostic enrichment at varying levels of screening stringency. RESULTS: We demonstrate that both modestly prognostic and strongly prognostic biomarkers can improve trial metrics using Biomarker Prognostic Enrichment Tool. Biomarker Prognostic Enrichment Tool is available as a webtool at http://prognosticenrichment.com and as a package for the R statistical computing platform. CONCLUSION: In some clinical settings, even biomarkers with modest prognostic performance can be useful for prognostic enrichment. In addition to the quantitative analysis provided by Biomarker Prognostic Enrichment Tool, investigators must consider the generalizability of trial results and evaluate the ethics of trial eligibility criteria.
Authors: Kathleen F Kerr; Allison Meisner; Heather Thiessen-Philbrook; Steven G Coca; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2014-05-22 Impact factor: 8.237
Authors: Steven G Coca; Amit X Garg; Heather Thiessen-Philbrook; Jay L Koyner; Uptal D Patel; Harlan M Krumholz; Michael G Shlipak; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2013-12-19 Impact factor: 10.121
Authors: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245
Authors: Girish N Nadkarni; Kinsuk Chauhan; Divya A Verghese; Chirag R Parikh; Ron Do; Carol R Horowitz; Erwin P Bottinger; Steven G Coca Journal: Kidney Int Date: 2018-04-25 Impact factor: 10.612
Authors: N T Ayas; A J Hirsch Allen; N Fox; B Peres; M Mehrtash; K H Humphries; R Jen; C M Taylor; S F van Eeden Journal: Lung Date: 2019-05-14 Impact factor: 2.584
Authors: Chirag R Parikh; Caroline Liu; Maria K Mor; Paul M Palevsky; James S Kaufman; Heather Thiessen Philbrook; Steven D Weisbord Journal: Am J Kidney Dis Date: 2019-09-20 Impact factor: 8.860
Authors: Kathleen F Kerr; Eric R Morenz; Heather Thiessen-Philbrook; Steven G Coca; F Perry Wilson; Peter P Reese; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2019-11-01 Impact factor: 8.237
Authors: Jason H Greenberg; Michael Zappitelli; Yaqi Jia; Heather R Thiessen-Philbrook; Christina A de Fontnouvelle; F Perry Wilson; Steven Coca; Prasad Devarajan; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2018-02-22 Impact factor: 10.121
Authors: Simke W Waijer; Taha Sen; Clare Arnott; Bruce Neal; Jos G W Kosterink; Kenneth W Mahaffey; Chirag R Parikh; Dick de Zeeuw; Vlado Perkovic; Brendon L Neuen; Steven G Coca; Michael K Hansen; Ron T Gansevoort; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2021-12-07 Impact factor: 8.237
Authors: Sarah J Schrauben; Haochang Shou; Xiaoming Zhang; Amanda Hyre Anderson; Joseph V Bonventre; Jing Chen; Steven Coca; Susan L Furth; Jason H Greenberg; Orlando M Gutierrez; Joachim H Ix; James P Lash; Chirag R Parikh; Casey M Rebholz; Venkata Sabbisetti; Mark J Sarnak; Michael G Shlipak; Sushrut S Waikar; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Jeffrey R Schelling Journal: J Am Soc Nephrol Date: 2020-10-29 Impact factor: 14.978